- MeSH
- Antidepressive Agents adverse effects therapeutic use MeSH
- Depressive Disorder, Treatment-Resistant * etiology drug therapy complications MeSH
- Depressive Disorder etiology drug therapy complications MeSH
- Myocardial Infarction * complications MeSH
- Cardiovascular Agents adverse effects MeSH
- Cardiovascular Diseases chemically induced MeSH
- Comorbidity MeSH
- Humans MeSH
- Moclobemide administration & dosage therapeutic use MeSH
- Parkinsonian Disorders chemically induced MeSH
- Aged MeSH
- Serotonin Syndrome drug therapy physiopathology prevention & control MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Case Reports MeSH
- MeSH
- Antidepressive Agents * therapeutic use MeSH
- Bupropion therapeutic use MeSH
- Adult MeSH
- Libido drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Moclobemide therapeutic use MeSH
- Orgasm drug effects MeSH
- Retrospective Studies MeSH
- Sexual Dysfunctions, Psychological * drug therapy MeSH
- Trazodone therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Female MeSH
- Keywords
- venlafaxin, duloxetin, Aurorix, agomelatin, tianeptin, Jarsin,
- MeSH
- Antidepressive Agents, Second-Generation pharmacology contraindications adverse effects therapeutic use MeSH
- Antidepressive Agents, Tricyclic pharmacology contraindications adverse effects therapeutic use MeSH
- Antidepressive Agents * MeSH
- Bupropion administration & dosage pharmacology contraindications metabolism adverse effects therapeutic use MeSH
- Fluvoxamine contraindications MeSH
- Gastrointestinal Hemorrhage MeSH
- Cytochrome P-450 CYP2D6 Inhibitors MeSH
- Monoamine Oxidase Inhibitors administration & dosage pharmacology classification contraindications therapeutic use MeSH
- Adrenergic Uptake Inhibitors pharmacology contraindications metabolism adverse effects therapeutic use MeSH
- Codeine administration & dosage metabolism therapeutic use MeSH
- Drug Interactions * MeSH
- Humans MeSH
- Melatonin agonists pharmacology contraindications therapeutic use MeSH
- Mianserin analogs & derivatives economics pharmacology contraindications metabolism therapeutic use MeSH
- Mirtazapine MeSH
- Moclobemide administration & dosage pharmacology contraindications metabolism adverse effects therapeutic use MeSH
- Drug-Related Side Effects and Adverse Reactions * MeSH
- Selective Serotonin Reuptake Inhibitors administration & dosage pharmacology contraindications adverse effects therapeutic use MeSH
- Serotonin Syndrome MeSH
- Arrhythmias, Cardiac MeSH
- Tramadol administration & dosage metabolism therapeutic use MeSH
- Trazodone administration & dosage pharmacology contraindications adverse effects therapeutic use MeSH
- Hypericum metabolism drug effects MeSH
- Check Tag
- Humans MeSH
OBJECTIVE: Monoamine oxidase (MAO), the enzyme responsible for metabolism of monoamine neurotransmitters, has an important role in the brain development and function, and MAO inhibitors have a range of potential therapeutic uses. We investigated systematically in vitro effects of pharmacologically different antidepressants and mood stabilizers on MAO activity. Methods: Effects of drugs on the activity of MAO were measured in crude mitochondrial fraction isolated from cortex of pig brain, when radiolabeled serotonin (for MAO-A) or phenylethylamine (for MAO-B) was used as substrate. The several antidepressants and mood stabilizers were compared with effects of well known MAO inhibitors such as moclobemide, iproniazid, pargyline, and clorgyline. Results: In general, the effect of tested drugs was found to be inhibitory. The half maximal inhibitory concentration, parameters of enzyme kinetic, and mechanism of inhibition were determined. MAO-A was inhibited by the following drugs: pargyline > clorgyline > iproniazid > fluoxetine > desipramine > amitriptyline > imipramine > citalopram > venlafaxine > reboxetine > olanzapine > mirtazapine > tianeptine > moclobemide, cocaine > lithium, valproate. MAO-B was inhibited by the following drugs: pargyline > clorgyline > iproniazid > fluoxetine > venlafaxine > amitriptyline > olanzapine > citalopram > desipramine > reboxetine > imipramine > tianeptine > mirtazapine, cocaine > moclobemide, lithium, valproate. The mechanism of inhibition of MAOs by several antidepressants was found various. Conclusions: It was concluded that MAO activity is acutely affected by pharmacologically different antidepressants at relatively high drug concentrations; this effect is inhibitory. There are differences both in inhibitory potency and in mechanism of inhibition between both several drugs and the two MAO isoforms. While MAO inhibition is not primary biochemical effect related to their therapeutic action, it can be supposed that decrease of MAO activity may be concerned in some effects of these drugs on serotonergic, noradrenergic, and dopaminergic neurotransmission.
- MeSH
- Affect drug effects MeSH
- Amitriptyline pharmacology MeSH
- Antidepressive Agents pharmacology MeSH
- Antimanic Agents pharmacology MeSH
- Benzodiazepines pharmacology MeSH
- Citalopram pharmacology MeSH
- Cyclohexanols pharmacology MeSH
- Desipramine pharmacology MeSH
- Fluoxetine pharmacology MeSH
- Imipramine pharmacology MeSH
- Monoamine Oxidase Inhibitors pharmacology MeSH
- Iproniazid pharmacology MeSH
- Clorgyline pharmacology MeSH
- Cocaine pharmacology MeSH
- Valproic Acid pharmacology MeSH
- Lithium pharmacology MeSH
- Mianserin analogs & derivatives pharmacology MeSH
- Mitochondria drug effects enzymology MeSH
- Moclobemide pharmacology MeSH
- Monoamine Oxidase drug effects metabolism MeSH
- Morpholines pharmacology MeSH
- Cerebral Cortex cytology MeSH
- Pargyline pharmacology MeSH
- Swine MeSH
- In Vitro Techniques MeSH
- Thiazepines pharmacology MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- MeSH
- Depression diagnosis etiology therapy MeSH
- Fluoxetine therapeutic use MeSH
- Phototherapy methods utilization MeSH
- Cognitive Behavioral Therapy methods MeSH
- Humans MeSH
- Moclobemide therapeutic use MeSH
- Mass Screening methods MeSH
- Surveys and Questionnaires MeSH
- Sertraline therapeutic use MeSH
- Seasonal Affective Disorder diagnosis epidemiology therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Randomized Controlled Trial MeSH
- MeSH
- Antidepressive Agents administration & dosage pharmacology MeSH
- Bupropion administration & dosage pharmacology MeSH
- Libido drug effects MeSH
- Humans MeSH
- Moclobemide administration & dosage pharmacology MeSH
- Placebo Effect MeSH
- Review Literature as Topic MeSH
- Sexual Dysfunctions, Psychological diagnosis etiology drug therapy MeSH
- Trazodone administration & dosage pharmacology MeSH
- Women MeSH
- Check Tag
- Humans MeSH
Autorka podává přehled prací, které sledovaly efekt vybraných antidepresiv v léčbě sexuálních dysfunkcí u mužů. Antidepresiva stimulující sexuální aktivitu (moklobemid, trazodon, bupropion) se osvědčila při léčbě poruch libida a erektilní dysfunkce, serotoninergní antidepresiva patří k lékům volby předčasné ejakulace.
The author describes studies of therapeutic efficaccy of antidepressants in the treatment of male sexual dysfunction. Antidepressants stimulating sexual activity (moclobemide, bupropion, trazodone) demonstrate good results in the therapy of decreased libido and erectile dysfunction, serotonergic antidepressants are used in the treatment of premature ejaculation.
- MeSH
- Antidepressive Agents pharmacology therapeutic use MeSH
- Bupropion administration & dosage pharmacology MeSH
- Depression drug therapy MeSH
- Humans MeSH
- Moclobemide administration & dosage pharmacology MeSH
- Selective Serotonin Reuptake Inhibitors administration & dosage pharmacology MeSH
- Sexual Dysfunctions, Psychological diagnosis etiology drug therapy MeSH
- Trazodone administration & dosage pharmacology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Review MeSH
Moklobemid je z pohledu kardiologického bezpečné antidepresivum, které nemá vedlejší účinky na kardiovaskulární aparát. Lze využít i jeho pozitivní vliv na erektilní dysfunkce.
Moclobemide is from a cardiological point of view a safe antidepressant without any adverse cardiovacular side effects. Moclobemide can also be successfully used in patients with ischemic heart disease and with erectile dysfunction.
- Keywords
- Aurorix,
- MeSH
- Antidepressive Agents administration & dosage adverse effects MeSH
- Depressive Disorder drug therapy MeSH
- Erectile Dysfunction MeSH
- Cardiovascular Diseases MeSH
- Comorbidity MeSH
- Humans MeSH
- Moclobemide administration & dosage MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
Klasická migréna je primární bolest hlavy. Preventivní léčbu používáme při nedostatečném účinku léčby akutní. 45 pacientů užívalo moklobemid při preventivní léčbě 300–600 mg denně, průměrně 8–12 měsíců. Kromě 4 se u všech frekvence i síla záchvatů zmenšila.
The classic migraine is the primary headache. Preventive treatment is used in the case of insufficient improvement from direct treatment. 45 patients took 300–600 mg of moclobemide per day. The frequency and strenght of the migraine attacks were reduced.
